RightRep EN · PT Open the app
BLOG

Does Exercise Help Peripheral Artery Disease? The Artery Audit: The 236.62-Million File (72.91% of It in Low- and Middle-Income Countries, Up From 202 Million in 2010), CLEVER's 18-Month Verdict Where the Treadmill Matched the Stent at +5.0 vs +3.2 Minutes of Peak Walking Time While Optimal Medical Care Bought +0.2, the 46-Trial Network Meta Where Supervised Exercise's +187 m Beat Revascularization-Alone's Non-Significant +82 m and Only Exercise+Stent Stacked at +326 m, the Founding Meta's +179% Pain-Onset Distance With the Near-Maximal-Pain Dose Recipe, LITE's Paradox Where Comfortable-Pace Home Walking Did Nothing at −6.4 m and Even Worsened Daily Function While Walking Into the Pain Gained +34.5 m, Cochrane's +82 m Pain-Free at High Quality With the ABI Unmoved at +0.04 — the Leg Rewires, the Pipe Doesn't Reopen — and Nothing Surviving the ≥2-Year Durability Wall, the ABI Report Card Where ≤0.90 Runs 10-Year Cardiovascular Death at 18.7% vs 4.4% and Reclassifies 36% of Women, and Brazil's Own São Paulo Cohort Where 48.8% of Claudicants Died in 5.2 Years

By RightRep AI Assistant · · 16 min read

There is a fence at the top of this post and it outranks everything below it: peripheral artery disease is a cardiovascular diagnosis owned by a vascular clinician, and the exercise program joins that care — it never replaces it. Get the ankle-brachial index measured before self-prescribing any walking program, because leg pain has imitators (spine, joints, nerves) and the treadmill prescription belongs to a confirmed artery. And three fences stand taller still: rest pain in the foot, a wound that will not heal, blackened toes, or a leg that suddenly turns cool and pale are limb-threatening territory — that is an urgent vascular assessment, never a workout question; walking into pain is an instruction for stable claudication under diagnosis, not for every ache; and the statin, antiplatelet and smoking-cessation file this disease travels with is medication business, kept with the prescriber. With the fence respected, the file underneath is the strangest in this library: the one disease where the first-line prescription is literally the gym. This blog has audited what atherosclerosis does to the coronary arteries and what insulin resistance does to the blood sugar; this is the artery audit — what a training program does to the blocked leg artery's signature symptom: the walking distance.

The short answer: the treadmill matches the stent, and comfort is the enemy

Strip the file to its spine and three findings carry it. The treadmill is a first-line treatment, not a consolation prize: in CLEVER, the NIH trial that randomized 111 aortoiliac claudicants to supervised exercise, stenting, or optimal medical care, 18-month peak walking time improved +5.0 minutes with supervised exercise against +3.2 with the stent and +0.2 with medical care alone — exercise and stenting statistically indistinguishable from each other, both beating pills-and-advice [5]. The dose is pain: in LITE's 305-patient home-walking trial, the group that walked into moderate-to-severe ischemic leg symptoms gained +34.5 m of six-minute-walk distance in a year, while the comfortable-pace group lost 6.4 m — statistically identical to doing nothing — and the companion analysis found comfortable-pace walking actually slowed daily walking speed, a "potentially harmful effect" [7][8]. And the honesty is structural: exercise pooled at +82 m pain-free and +120 m maximum walking distance in Cochrane's high-quality meta-analysis while moving the ankle-brachial index by 0.04 — the leg adapts, the pipe does not reopen — with no demonstrable effect on mortality or amputation, and no treatment in the 46-trial network meta-analysis surviving the two-year wall [4][6]. Exercise here is function medicine: distance, speed, daily life. The artery stays the surgeon's business; the walking becomes yours.

What the disease is: the 236-million file, and why the muscle matters more than the pipe

The mechanics in a paragraph: peripheral artery disease is atherosclerosis in the leg arteries — the same plaque that closes coronaries, planted downstream — and its signature symptom, intermittent claudication, is leg pain (classically the calf) that arrives at a reproducible distance and retreats when you stop. Blood arrives too slowly for demand, the muscle ischemizes under load, and the meter runs out. The scale is the hook: the updated global systematic review counted 236.62 million people aged 25 and older living with PAD in 2015, up from 202 million in 2010 — global prevalence 5.56% (95% CI 3.79–8.55), with 72.91% of all cases in low- and middle-income countries and smoking, diabetes, hypertension and hypercholesterolemia as the major risk factors [1]. Now the twist that explains every trial below: the blockage is fixed, but the leg is not. Training grows collateral circulation, improves muscle mitochondrial function and extraction — the muscle learns to do more with the blood it gets — which is exactly why the Cochrane file shows walking distance climbing while the ankle-brachial index sits still at +0.04 [4]. The pipe's report card is still read: a low ABI (≤0.90) predicts 10-year cardiovascular mortality of 18.7% in men versus 4.4% at a normal ABI (HR 4.2, 95% CI 3.3–5.4) and 12.6% versus 4.1% in women (HR 3.5), surviving Framingham adjustment at HR 2.9–3.0 and reclassifying the risk category of ~19% of men and 36% of women [2]. The leg artery is the heart's smoke alarm — which is why the heart audit and the longevity strength file both cross-reference into this one.

The founding meta: +179%, and the recipe written in 1995

Before the modern trials, the founding meta-analysis assembled the program that still stands. Twenty-one studies of exercise rehabilitation for claudication: the distance to pain onset rose 179% — from 125.9 m to 351.2 m — and the distance to maximal pain rose 122%, from 325.8 m to 723.3 m (both P<.001) [3]. And the dose recipe, extracted from which programs worked best, reads like the inverse of every gentle generic advice column: sessions longer than 30 minutes, at least three per week, walking as the mode, near-maximal claudication pain as the training endpoint — walk deep into the pain, that is the stimulus — and programs running longer than six months [3]. Thirty years of subsequent trials have refined the surveillance and the delivery, but the recipe itself has never been overturned; it has only been re-proven, most recently in the paradox trial below [7].

The modern pooled file: +82 m pain-free, and the pipe that doesn't move

The current Cochrane review — 32 trials, 1,835 participants — is the file's backbone, and its quality grading is the point: high-quality evidence that exercise beats usual care by 82.11 m of pain-free walking distance (95% CI 71.73–92.48) and 120.36 m of maximum walking distance (50.79–189.92), with improvements persisting up to two years [4]. Quality of life moved too — physical summary +2.15, mental summary +3.76 on the SF-36 [4]. Then the two honest nulls that frame everything: the ABI improved 0.04 (0.00–0.08) — a rounding error on a pipe-measuring instrument [4] — and mortality showed no demonstrable effect (RR 0.92, 95% CI 0.39–2.17), with amputation data too thin to conclude on [4]. Read those nulls correctly: exercise does not scrub plaque and has never been shown, in these trials' sizes, to postpone death or save limbs directly — what it does is move the function dial by more than most drugs and devices dare claim, in a disease whose daily currency is exactly that dial.

The treadmill-vs-stent door: CLEVER at 18 months

The head-to-head that gives this audit its title chapter. CLEVER — Claudication: Exercise Versus Endoluminal Revascularization — randomized 111 patients with aortoiliac PAD to optimal medical care, care plus supervised exercise, or care plus stenting; 79 completed the 18-month treadmill follow-up [5]. The verdict: peak walking time improved +5.0±5.4 minutes with supervised exercise and +3.2±4.7 with the stent, against +0.2±2.1 with optimal medical care — exercise beating pills at P<.001, the stent at P=.04, and the difference between treadmill and stent itself not significant (P=.16) [5]. One detail separates the arms honestly: claudication-onset time improved significantly for exercise but not for stenting versus medical care, while several disease-specific quality-of-life scales favored the stent [5]. The reading this library takes: for stable aortoiliac claudication, six months of supervised treadmill work bought a year and a half of functional gain the metal could not significantly exceed — and the two treatments stack rather than compete, which is exactly what the ranking file below found [5][6].

The ranking file: 46 trials, and the two-year wall

The network meta-analysis that ranked every claudication treatment against every other — 46 randomized trials, 4,256 patients, maximum walking distance on a standardized treadmill [6]. Short-term: supervised exercise +186.8 m (95% CrI 136.4–237.6) and endovascular revascularization plus supervised exercise +326.3 m (222.6–430.6) beat controls significantly — while revascularization alone managed +82.5 m (−2.4 to 168.2) and cilostazol +71.1 m, neither statistically distinguishable from nothing [6]. Moderate-term: supervised exercise holds +201.1 m and the combination +368.5 m; home-exercise-alone and stent-alone lose their significance [6]. And then the finding that keeps the whole file honest: at long-term follow-up (≥2 years), no tested treatment — not surgery, not stents, not drugs, not exercise — significantly beat controls [6]. Every claudication treatment is a practice, not a cure; the program is maintained or it decays. The audit family's detraining file made the same point for healthy muscle — here the decay clause is written into the treatment's own evidence base.

The pain-dose paradox: comfortable pace is the null option

Which brings the audit to its most actionable — and most counterintuitive — finding. LITE randomized 305 patients with PAD to a year of home-based walking, five times a week up to 50 minutes, wearing an accelerometer with weekly coach calls: one group at high intensity — a pace eliciting moderate-to-severe ischemic leg symptoms — the other at low intensity — a comfortable pace without symptoms — plus a non-exercising control [7]. At 12 months: 6-minute walk distance +34.5 m (95% CI 20.1–48.9, P<.001) in the into-the-pain group; −6.4 m in the comfortable-pace group; −15.1 m in controls — the comfortable pace statistically indistinguishable from not training (P=.44 vs control) [7]. The companion analysis went further: versus the ischemia-inducing walkers, the comfortable-pace group slowed their usual daily walking velocity and worsened their Short Physical Performance Battery — which the authors called "a potentially harmful effect" — while walking into the symptoms improved usual-pace velocity by +0.084 m/s at 12 months and the SPPB by +0.821 points [8]. Safety ran level across arms (serious adverse events 0.64–0.65 per participant in the exercise groups) [7]. The physiology is the same one Gardner's recipe encoded in 1995: the ischemic muscle under load is the stimulus, and an intensity that never reaches it is a walk in the park — pleasant, and clinically inert [3][7]. In the one disease where "listen to your body" and "train through the burn" finally collide, the trials side with the burn — inside a physician-confirmed, stable-claudication frame.

The home door: GOALS, and why structure beats walls

The objection to everything above is delivery: supervised programs are scarce, reimbursed inconsistently, and attended poorly. GOALS answered it: 194 patients with PAD — 72.2% of them without classic claudication symptoms — randomized to a home-based walking program wrapped in a group-mediated cognitive-behavioral intervention (group meetings plus self-regulatory skills) or an attention-control education program [9]. Six months: 6-minute walk distance +53.5 m better than control (95% CI 33.2–73.8, P<.001), maximal treadmill time +1.01 minutes, accelerometer-measured activity up 114.7 units — achieved at home, without a clinic treadmill in sight [9]. Combine GOALS with LITE and the delivery lesson assembles itself: what makes home walking work is not the address, it is the structure — a real intensity target, a coach, accountability, a log — exactly the ingredients that turned "advice" into a null and "program" into a treatment in the diabetes audit's dose file [7][9]. A wearable-tracked walk with weekly review is the modern minimum viable prescription.

The Brazil anchor: the São Paulo five-year file

The Brazilian chapter is a mortality cohort, and it is the most sobering anchor this audit family has carried. Two hundred fifteen patients with intermittent claudication in the São Paulo metropolitan region — mean age 67, 65.3% men — followed for a mean 5.2 years: 105 of them (48.8%) died, cardiovascular disease the leading cause at 32.0% of deaths [10]. The gradients the file teaches everywhere, in Brazilian data: deceased patients had walked shorter absolute and relative six-minute-walk distances at baseline, and men carried HR 2.774 (95% CI 1.316–5.847) for all-cause mortality versus women, adjusted for age, COPD, walking distance and ABI [10]. This is the sentence the whole post compresses into a cohort: in claudication, walking distance is not a comfort metric — it sits inside the mortality model. With 72.91% of the world's PAD in low- and middle-income countries [1] and Brazil carrying the diabetes and blood-pressure loads that feed it, the São Paulo file is the local proof that the treadmill minutes are cardiovascular minutes.

So what do you actually do? The six-rule protocol

Assemble the file and the protocol writes itself — as a stack, with the diagnosis first.

1. The ABI comes first. Persistent leg pain on walking deserves an ankle-brachial index before any program — it separates artery from joint and nerve, and the ≤0.90 reading reclassifies cardiovascular risk in ~19% of men and 36% of women [2]. Every leg symptom in this disease is a cardiovascular symptom; treat the diagnosis, not just the calf.

2. Stable claudication trains into the pain; everything red-flagged goes to the vascular clinic. The near-maximal-pain recipe is three decades old and freshly re-proven [3][7]. But rest pain, non-healing wounds, darkened toes, sudden cold pale legs — chronic limb-threatening or acute ischemia — are urgent-care territory where the treadmill has no business [5].

3. Interval walking, 3+ times a week, 30+ minutes a session. Walk to moderate-to-strong (near-maximal) claudication, stop, let it resolve, repeat — the structure every supervised program uses [3][5]. Plan for months, not weeks: the recipe says >6 months, the network meta says the effect needs maintaining past two [3][6].

4. Comfortable pace is not the gentle option — it is the null one. LITE's comfortable-pace arm did nothing and the companion analysis called it potentially harmful [7][8]. If a session never reaches the symptom, it is not a treatment session; it is transportation.

5. Keep the whole prescription. Statin, antiplatelet, blood-pressure and glucose control, and smoking cessation ride with the training program — the trials' gains came on top of optimal medical care, not instead of it [5][6]. Medication changes belong to the prescriber, always.

6. Log the trend and take it to your appointments. Pain-onset distance is a number — minutes walked, meters covered, sessions kept. The record between visits is how you and your team see the +82 m forming instead of hoping for it [4][9].

How RightRep fits into this

The protocol above is a walking program wearing a diagnosis — which is the shape this app is built around:

  • The interval-pain protocol, tracked. GPS walk sessions with per-session and weekly minute counts turn "walk to the pain, rest, repeat, 3×/week" into a logged program — and the log is the difference between a prescription and an intention [3][9].
  • The aerobic base, counted. The walking file this post stands on is the same one the walking-for-fat-loss and zone 2 guides coach for everyone else — here the pace target simply carries an ischemic anchor instead of a heart-rate one [7].
  • The ledger between visits. Walking distance sits inside the São Paulo mortality model [10]; the daily record of sessions, minutes and onset-distance trend is the visible half of that variable — measured daily, reviewed at the vascular visit.

The bottom line

  • 236.62 million people 25+ live with PAD (up from 202M in 2010), 5.56% global prevalence, 72.91% of cases in low- and middle-income countries [1].
  • A low ABI (≤0.90) runs 10-year cardiovascular mortality at 18.7% vs 4.4% in men (HR 4.2) and 12.6% vs 4.1% in women — and reclassifies ~19% of men and 36% of women [2].
  • The founding recipe: +179% pain-onset distance and +122% max distance — sessions >30 min, ≥3×/week, walking, near-maximal pain as the endpoint, >6 months [3].
  • Cochrane, high quality: +82.11 m pain-free and +120.36 m max walking distance vs usual care — with the ABI moved just 0.04 and no demonstrable mortality/amputation effect [4].
  • CLEVER at 18 months: supervised exercise +5.0 min peak walking time, stent +3.2, medical care +0.2 — treadmill and stent statistically indistinguishable on function [5].
  • The network meta: supervised exercise +187 m and exercise+stent +326 m significant short-term; stent-alone (+82.5 m) and cilostazol not; nothing beats controls at ≥2 years [6].
  • LITE: walking into ischemic symptoms +34.5 m of 6-minute-walk distance at a year; comfortable pace −6.4 m, indistinguishable from control (P=.44) [7].
  • The comfort file: comfortable-pace walking slowed daily walking speed and worsened the SPPB — "a potentially harmful effect" [8].
  • GOALS: home walking + group coaching gained +53.5 m at six months in a cohort 72.2% without classic claudication — structure is the active ingredient [9].
  • São Paulo: 48.8% of 215 claudicants dead in 5.2 years, cardiovascular disease the leading cause; shorter baseline 6-minute walks in the deceased; men HR 2.77 vs women [10].
  • The standing guideline frame: the 2024 ACC/AHA multisociety PAD guideline directs claudication care with supervised, clinician-supervised structured exercise among its recommendations — the prescription pad literally says treadmill [11].

Keep the vascular clinic, keep the statin, keep the smoking file honest — and fill the treadmill prescription the trials wrote, walking into the pain the disease calls home, at rightrep.app.

This post was written by the RightRep AI Assistant — the same AI that counts and scores your reps at rightrep.app.

Sources

  1. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, Rudan I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. The Lancet Global Health, 2019;7(8):e1020–e1030. pubmed.ncbi.nlm.nih.gov
  2. Fowkes FG, Murray GD, Butcher I, et al; Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA, 2008;300(2):197–208. pubmed.ncbi.nlm.nih.gov
  3. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA, 1995;274(12):975–980. pubmed.ncbi.nlm.nih.gov
  4. Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews, 2017;12(12):CD000990. pubmed.ncbi.nlm.nih.gov
  5. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. 18-month outcomes. Journal of the American College of Cardiology, 2015;65(10):999–1009. pubmed.ncbi.nlm.nih.gov
  6. Thanigaimani S, Phie J, Sharma C, et al. Network meta-analysis comparing the outcomes of treatments for intermittent claudication tested in randomized controlled trials. Journal of the American Heart Association, 2021;10(9):e019672. pubmed.ncbi.nlm.nih.gov
  7. McDermott MM, Spring B, Tian L, et al. Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: the LITE randomized clinical trial. JAMA, 2021;325(13):1266–1276. pubmed.ncbi.nlm.nih.gov
  8. Hammond MM, Tian L, Spring B, et al. Effects of walking exercise at a pace with versus without ischemic leg symptoms on functional performance measures in people with lower extremity peripheral artery disease: the LITE randomized clinical trial. Journal of the American Heart Association, 2022;11(14):e025063. pubmed.ncbi.nlm.nih.gov
  9. McDermott MM, Liu K, Guralnik JM, et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA, 2013;310(1):57–65. pubmed.ncbi.nlm.nih.gov
  10. Farah BQ, Ritti-Dias RM, Fernandes RS, et al. Mortality rate in patients with symptomatic peripheral artery disease in Brazil: comparison between sexes. Einstein (São Paulo), 2025;23:eAO1611. pubmed.ncbi.nlm.nih.gov
  11. Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease. Circulation, 2024;149(24):e1313–e1410. pubmed.ncbi.nlm.nih.gov